2
|
Pisár M, Schütznerová E, Hančík F, Popa I, Trávníček Z, Cankař P. Modification of Boc-Protected CAN508 via Acylation and Suzuki-Miyaura Coupling. Molecules 2018; 23:molecules23010149. [PMID: 29329219 PMCID: PMC6017724 DOI: 10.3390/molecules23010149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Revised: 12/21/2017] [Accepted: 01/11/2018] [Indexed: 11/16/2022] Open
Abstract
The cyclin-dependent kinase inhibitor, CAN508, was protected with di-tert-butyl dicarbonate to access the amino-benzoylated pyrazoles. The bromo derivatives were further arylated by Suzuki-Miyaura coupling using the XPhos Pd G2 pre-catalyst. The coupling reaction provided generally the para-substituted benzoylpyrazoles in the higher yields than the meta-substituted ones. The Boc groups were only utilized as directing functionalities for the benzoylation step and were hydrolyzed under conditions of Suzuki-Miyaura coupling, which allowed for elimination of the additional deprotection step.
Collapse
Affiliation(s)
- Martin Pisár
- Department of Organic Chemistry, Faculty of Science, Palacký University, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
| | - Eva Schütznerová
- Institute of Molecular and Translation Medicine, Faculty of Medicine, Palacký University, Hněvotínská 5, 779 00 Olomouc, Czech Republic.
| | - Filip Hančík
- Department of Organic Chemistry, Faculty of Science, Palacký University, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
| | - Igor Popa
- Department of Inorganic Chemistry, Faculty of Science, Palacký University, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
| | - Zdeněk Trávníček
- Department of Inorganic Chemistry, Faculty of Science, Palacký University, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
| | - Petr Cankař
- Department of Organic Chemistry, Faculty of Science, Palacký University, 17. listopadu 1192/12, 771 46 Olomouc, Czech Republic.
| |
Collapse
|
4
|
Meredith EL, Mainolfi N, Poor S, Qiu Y, Miranda K, Powers J, Liu D, Ma F, Solovay C, Rao C, Johnson L, Ji N, Artman G, Hardegger L, Hanks S, Shen S, Woolfenden A, Fassbender E, Sivak JM, Zhang Y, Long D, Cepeda R, Liu F, Hosagrahara VP, Lee W, Tarsa P, Anderson K, Elliott J, Jaffee B. Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration. J Med Chem 2015; 58:9273-86. [PMID: 26568411 DOI: 10.1021/acs.jmedchem.5b01227] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The benefit of intravitreal anti-VEGF therapy in treating wet age-related macular degeneration (AMD) is well established. Identification of VEGFR-2 inhibitors with optimal ADME properties for an ocular indication provides opportunities for dosing routes beyond intravitreal injection. We employed a high-throughput in vivo screening strategy with rodent models of choroidal neovascularization and iterative compound design to identify VEGFR-2 inhibitors with potential to benefit wet AMD patients. These compounds demonstrate preferential ocular tissue distribution and efficacy after oral administration while minimizing systemic exposure.
Collapse
Affiliation(s)
- Erik L Meredith
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Nello Mainolfi
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Stephen Poor
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Yubin Qiu
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Karl Miranda
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - James Powers
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Donglei Liu
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Fupeng Ma
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Catherine Solovay
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Chang Rao
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Leland Johnson
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Nan Ji
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Gerald Artman
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Leo Hardegger
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Shawn Hanks
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Siyuan Shen
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Amber Woolfenden
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Elizabeth Fassbender
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Jeremy M Sivak
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Yiqin Zhang
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Debby Long
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Rosemarie Cepeda
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Fang Liu
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Vinayak P Hosagrahara
- Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge Massachusetts 02139, United States
| | - Wendy Lee
- Metabolism and Pharmacokinetics, Novartis Institutes for BioMedical Research , 250 Massachusetts Avenue, Cambridge Massachusetts 02139, United States
| | - Peter Tarsa
- Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Karen Anderson
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Jason Elliott
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research , 100 Technology Square, Cambridge, Massachusetts 02139, United States
| | - Bruce Jaffee
- Ophthalmology, Novartis Institutes for BioMedical Research , 500 Technology Square, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
5
|
Nencini A, Castaldo C, Comery TA, Dunlop J, Genesio E, Ghiron C, Haydar S, Maccari L, Micco I, Turlizzi E, Zanaletti R, Zhang J. Design and synthesis of a hybrid series of potent and selective agonists of α7 nicotinic acetylcholine receptor. Eur J Med Chem 2014; 78:401-18. [PMID: 24704613 DOI: 10.1016/j.ejmech.2014.03.031] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2013] [Revised: 02/10/2014] [Accepted: 03/11/2014] [Indexed: 11/29/2022]
Abstract
α7 nicotinic acetylcholine receptor agonists are promising therapeutic candidates for the treatment of cognitive impairment. As a follow up of our internal medicinal chemistry program we investigated a novel series of α7 nAChR agonists. Starting from molecular docking studies on two series of molecules recently developed in our laboratories, an alternative scaffold was designed attempting to combine the optimal features of these previously identified urea and pyrazole compounds. Based on our previous SAR knowledge and on predicted drug-like properties, a small library was synthesized in parallel manner, affording compounds with excellent α7 nAChR activity, selectivity and preliminary ADME profile.
Collapse
Affiliation(s)
- Arianna Nencini
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy.
| | - Cristiana Castaldo
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Thomas A Comery
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| | - John Dunlop
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| | - Eva Genesio
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Chiara Ghiron
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Simon Haydar
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| | - Laura Maccari
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Iolanda Micco
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Elisa Turlizzi
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Riccardo Zanaletti
- Siena Biotech SpA, Strada del Petriccio e Belriguardo 35, 53100 Siena, Italy
| | - Jean Zhang
- Neuroscience Research Unit, Pfizer, Eastern Point Road, Groton, CT 06340, United States
| |
Collapse
|
7
|
Mitchell D, Cole KP, Pollock PM, Coppert DM, Burkholder TP, Clayton JR. Development and a Practical Synthesis of the JAK2 Inhibitor LY2784544. Org Process Res Dev 2011. [DOI: 10.1021/op200229j] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- David Mitchell
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Kevin P. Cole
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Patrick M. Pollock
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - David M. Coppert
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Timothy P. Burkholder
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| | - Joshua R. Clayton
- Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana 46285, United States
| |
Collapse
|
10
|
Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA. 3-Aminopyrazole Inhibitors of CDK2/Cyclin A as Antitumor Agents. 1. Lead Finding. J Med Chem 2004; 47:3367-80. [PMID: 15189033 DOI: 10.1021/jm031145u] [Citation(s) in RCA: 131] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Abnormal proliferation mediated by disruption of the normal cell cycle mechanisms is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDK) and cyclins, such as CDK2/cyclin A and CDK2/cyclin E, and inhibiting their kinase activity are regarded as promising antitumor agents to complement the existing therapies. From a high-throughput screening effort, we identified a new class of CDK2/cyclin A/E inhibitors. The hit-to-lead expansion of this class is described. X-ray crystallographic data of early compounds in this series, as well as in vitro testing funneled for rapidly achieving in vivo efficacy, led to a nanomolar inhibitor of CDK2/cyclin A (N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthyl)acetamide (41), PNU-292137, IC50 = 37 nM) with in vivo antitumor activity (TGI > 50%) in a mouse xenograft model at a dose devoid of toxic effects.
Collapse
Affiliation(s)
- Paolo Pevarello
- Chemistry Department, Pharmacia Italia, Viale Pasteur 10, 20014 Nerviano (MI), Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|